Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Christopher H. van Dyck et al.
Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
John R. Sims et al.
Summary: This study evaluated the efficacy and adverse events of donanemab, an antibody treatment for Alzheimer's disease. The findings showed that donanemab significantly slowed disease progression in patients with early symptomatic Alzheimer's disease.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Clinical Neurology
Rioghna R. Pittock et al.
Summary: Treatment options for Alzheimer's disease are limited, and research on the applicability of anti-beta-amyloid monoclonal antibodies in the general population is lacking. This study aims to assess the generalizability of anti-amyloid treatment and apply the eligibility criteria of two clinical trials to a population-based sample.
Article
Medicine, General & Internal
John R. Sims et al.
Summary: This study assessed the efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. The results showed that donanemab significantly slowed the clinical progression in individuals with early symptomatic Alzheimer disease and low/medium tau pathology, as well as in the combined population with low/medium and high tau pathology.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Review
Clinical Neurology
J. Cummings et al.
Summary: Lecanemab (Leqembi (R)) is approved for the treatment of Alzheimer's disease (AD) initiated in early stages with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) provide guidance for clinicians to administer lecanemab safely and effectively, considering the differences between clinical trial participants and community dwelling patients. AURs emphasize monitoring for adverse events, such as amyloid related imaging abnormalities (ARIA) and hemorrhages, especially in patients with APOE4 gene carriers.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2023)
Article
Clinical Neurology
J. Cummings et al.
Summary: Aducanumab (Aduhelm) has been approved in the United States for the treatment of patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. The update of the appropriate use recommendations (AURs) aims to refine the guidelines based on real-world use and provide better patient selection, decision-making, safety monitoring, and risk mitigation. The importance of detecting past medical conditions and performing APOE genotyping to prevent complications and improve detection of amyloid-related imaging abnormalities (ARIA) is emphasized. MRI is suggested for better monitoring, and additional parameters for treatment discontinuation are proposed considering recurrent or serious ARIA. This update does not address efficacy, price, or insurance coverage, and serves as a guide for clinicians.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2022)
Article
Clinical Neurology
S. Budd Haeberlein et al.
Summary: Aducanumab showed significant changes in early Alzheimer's disease patients in one trial, but did not meet primary or secondary endpoints in another study. Both trials demonstrated a dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE
(2022)
Letter
Medicine, General & Internal
Timothy S. Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Public, Environmental & Occupational Health
Rosebud O. Roberts et al.
